17.91

3.97% -0.74

After Hours: 17.84 -0.07 -0.39%

Cartesian Therapeutics Inc (RNAC)

Overview News Price History Option Chain Financials Discussions Forecast

Cartesian Therapeutics Inc stock is traded at $17.91, with a volume of 68,242. It is down -3.97% in the last 24 hours and down -12.97% over the past month. Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Previous Close:

$18.65

Open:

$18.77

24h Volume:

68,242

Relative Volume:

0.67

Market Cap:

$489.24M

Revenue:

$26.00M

Net Income/Loss:

$-219.71M

P/E Ratio:

EPS:

Net Cash Flow:

$-51.37M

1W Performance:

+5.73%

1M Performance:

-12.97%

6M Performance:

-27.11%

1Y Performance:

-49.19%

1-Day Range:

$17.74

$19.40

1-Week Range:

$16.50

$19.80

52-Week Range:

$11.66

$41.87

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name

Cartesian Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

301-348-8698

Address

7495 NEW HORIZON WAY, FREDERICK

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

RNAC's Discussions on Twitter

Compare RNAC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNAC Cartesian Therapeutics Inc	17.91	489.24M	26.00M	-219.71M	-51.37M	0.00
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform
May-24-24	Initiated	Mizuho	Buy
Apr-23-24	Reiterated	H.C. Wainwright	Buy
Apr-23-24	Initiated	Leerink Partners	Outperform
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform
Jun-14-22	Reiterated	Needham	Buy
Jun-06-22	Initiated	SVB Leerink	Outperform
Jun-15-21	Initiated	BTIG Research	Buy
Jan-26-21	Upgrade	Mizuho	Neutral → Buy
Oct-01-20	Downgrade	Mizuho	Buy → Neutral
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight
Jan-21-20	Initiated	William Blair	Outperform
Jun-27-18	Initiated	Janney	Buy
Mar-30-17	Reiterated	UBS	Buy

View All

Cartesian Therapeutics Inc Stock (RNAC) Latest News

Nov 27, 2024

Great Point Partners LLC Makes New Investment in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat

Nov 27, 2024

Needham & Company LLC Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World

Nov 27, 2024

Nov 26, 2024

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.33 - MarketBeat

Nov 26, 2024

Nov 25, 2024

Cartesian Therapeutics' (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat

Nov 25, 2024

Nov 22, 2024

Cartesian therapeutics CTO sells $649,029 in stock By Investing.com - Investing.com Nigeria

Nov 22, 2024

Cartesian therapeutics CTO sells $649,029 in stock - Investing.com India

Nov 22, 2024

Nov 21, 2024

Cartesian Therapeutics to Present Updated Data from Phase - GlobeNewswire

Nov 21, 2024

Cartesian Therapeutics to Present Key Phase 2b Trial Data for Myasthenia Gravis Treatment | RNAC Stock News - StockTitan

Nov 21, 2024

Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics - Simply Wall St

Nov 21, 2024

Nov 19, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpWhat's Next? - MarketBeat

Nov 19, 2024

Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million By Investing.com - Investing.com Nigeria

Nov 19, 2024

Nov 18, 2024

Cartesian Therapeutics executive sells $875,042 in stock By Investing.com - Investing.com Canada

Nov 18, 2024

Cartesian Therapeutics' chief medical officer sells shares worth $907,532 By Investing.com - Investing.com Canada

Nov 18, 2024

Cartesian therapeutics director Timothy Springer buys $7.37M in stock By Investing.com - Investing.com Canada

Nov 18, 2024

Cartesian therapeutics director Timothy Springer buys $7.37M in stock - Investing.com

Nov 18, 2024

Cartesian Therapeutics' chief medical officer sells shares worth $907,532 - Investing.com

Nov 18, 2024

Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million - Investing.com

Nov 18, 2024

Cartesian Therapeutics executive sells $875,042 in stock - Investing.com

Nov 18, 2024

Nov 17, 2024